Assess whether the primary endpoint will survive FDA scrutiny (b16ffb)

SITUATION The working file is inspection-readiness findings at a CMO after a DSMB note on an imbalance that is not yet a signal. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a DSMB note on an imbalance that is not yet a signal for pharmacovigilance medical reviewer. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision the primary endpoint will turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in inspection-readiness findings at a CMO, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter